How Will Open Technology Standards Improve Clinical Trials?
Pharma Tech Outlook

How Will Open Technology Standards Improve Clinical Trials?

Pharma Tech Outlook | Friday, July 12, 2019

The establishment of open technology standards will enable pharmaceutical companies to introduce enhanced connectivity and efficiency into the clinical trials when collaborating with CROs.

FREMONT, CA – The life science industry has experienced tremendous growth over the last few years. The innovation has accelerated the flow of drugs into the market. In the year 2018 alone, 59 drugs were approved for medical use. Although it has given great hope for personalized treatments, the cost of developing complex therapies has dramatically escalated.

Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.

Presently, the average cost of phase II clinical trials can range from $7 to $19.6 million, whereas in the case of Phase III clinical trials, it is as high as $52.9 million. Also, trials have prolonged timelines and can contribute to study delays and expenses. Although several sponsors hire contract research organizations (CROs) to conduct clinical trials, the absence of uniformity in data can drive up the time and cost needed to introduce new medicine in the market. The disparate systems and standards also make information sharing a challenging task.

Clinical outsourcing is being leveraged by sponsors to conduct almost all the phases of drug development, including preclinical research, clinical testing, and post-approval functions such as monitoring, consulting, commercialization, and safety management. Since many of the organizations plan on contracting multiple specialized services, it will introduce more complexity in terms of collaboration. The CROs often utilize disconnected technologies to conduct their tasks, which create more obstacles in the way of effective communication and data exchange.

Check Out:- Top CRO Companies

The information exchange is often carried out through e-mail, which might require manual reentry into different systems. There is little visibility in the processes, which often forces the sponsors to conduct regular audits to maintain accuracy in the data. Ultimately, it is not the CROs, but the pharmaceutical companies which hold responsibility for the clinical trials.

The implementation of a connected clinical network bolstered by open technology standards can significantly enhance productivity, reduce expenses, and streamline the clinical trials. Also, it can help the organizations in addressing the collaboration and technology challenges involved in the trial operations.

Several technology providers such as Veeva Systems are gathering input from the industry at large and collaborating with research organizations to develop open technology standards. Their purpose is to streamline information sharing during trials and offer enhanced visibility to the sponsors when working with CROs. The common standards will allow both parties to enhance efficiency and mitigate the risks involved in the clinical trials.

Check This Out: Top MedTech Startups Companies

More in News

In recent years, researchers combining computer science and biology have found it relatively easy to obtain funding to bring their innovations to the commercial market. The idea was simple: by leveraging large datasets, machine learning could overcome longstanding challenges in drug discovery, development, and testing. Nevertheless, many of these initial drug initiatives have encountered difficulties. It is crucial for both the field and patients to comprehend the reasons behind these setbacks and to address these developmental challenges. Patient Data is Fundamental Transferring cutting-edge knowledge from academic laboratories to address specific technical challenges using clearly defined datasets has been established as a successful strategy in technology and biotechnology. However, integrating Artificial Intelligence (AI) into medicine—frequently referred to as 'techbio'—tends to comprehensively emphasize biological aspects over technological ones. The data essential for success in this domain is typically more diverse, sourced from various locations, and, importantly, derived from actual patients within the intricate landscape of different healthcare environments. Staying Close to Academia: In the development of medicine, human intelligence must take precedence over artificial intelligence both initially and subsequently. This intelligence is predominantly found within universities and research hospitals. Therefore, a vital component in enhancing the efficacy of AI in the creation of superior medical solutions is the establishment of robust and enduring collaborations with these academic and research institutions. This process is not merely unidirectional; it constitutes a network of continuous engagement among academia, pharmaceutical companies, and biotechnology firms. Innovative collaboration methods, such as privacy-preserving federated learning, enable training machine learning models on extensive multimodal datasets without the need to transfer them. This approach can significantly advance fundamental research, diagnostics, and drug discovery, yielding numerous patient advantages while safeguarding privacy and optimizing the utilization of diverse data sources. Multi-Dimensional Problems Require Multimodal Data: At this point in the evolution of artificial intelligence within medicine, it is evident that AI provides us with a novel perspective on human biology. For instance, a single digital pathology slide encompasses a volume of data comparable to that of a feature-length film, and only through machine learning can we fully leverage this information. However, to comprehend diseases and influence their trajectories, it is crucial to acknowledge the intricate nature of biology across all levels—from molecules to cells, tissues, the disease microenvironment, and the organism in its entirety. To achieve this, advancing AI capabilities beyond unimodal tasks is imperative. We must integrate medical imaging with cutting-edge molecular profiling technologies that capture the activity and localization of biomolecules, known as spatial omics, thereby connecting the microscopic with the macroscopic. By combining AI with such comprehensive datasets, we can gain insights into diseases, from their predisposition to their progression and treatment. ...Read more
Drug discovery is a complex, multi-step process focused on identifying new therapeutic compounds and delivering them to market. Despite progress in technology and science, the path from discovery to an approved drug remains filled with challenges. These include high costs, extended timelines, and scientific uncertainties. This article examines the main hurdles in drug discovery and outlines strategies to overcome them. High Costs and Financial Risks One of the primary obstacles in drug discovery is the substantial financial burden linked to research and development (R&D). Typically, the process requires more than ten years and expenditures amounting to billions of dollars before introducing a new drug. The financial risk is substantial, as many potential drugs fail during clinical trials, leading to significant losses for pharmaceutical companies. Investment in Early-Stage Research: To mitigate financial risks, companies increasingly invest in early-stage research to identify promising compounds before committing to expensive clinical trials. Collaborations and Partnerships: Strategic partnerships with academic institutions, biotech firms, and other pharmaceutical companies can help share the financial burden and pool resources for drug development. Lengthy Timelines The drug discovery process is notoriously time-consuming. It involves multiple stages, including target identification; lead compound discovery, preclinical testing, and clinical trials. Each stage can take several years, and delays are common due to regulatory requirements and unforeseen scientific challenges. Streamlining Processes: Implementing efficient project management practices and leveraging technology can help streamline the drug discovery process. For example, using artificial intelligence (AI) and machine learning (ML) to analyze data can accelerate target identification and lead optimization. Regulatory Collaboration: Engaging with regulatory agencies early in development can help identify potential hurdles and expedite approval. Scientific Complexities Drug discovery is inherently complex due to the biological intricacies of diseases and the need for precise targeting of therapeutic compounds. Understanding disease mechanisms, identifying suitable targets, and designing effective drugs require advanced scientific knowledge and sophisticated technologies. Advanced Technologies: Cutting-edge technology such as CRISPR gene editing, high-throughput screening, and computer modeling can help us understand disease causes and improve medication design. Interdisciplinary Approaches: Combining expertise from various scientific disciplines, including biology, chemistry, and pharmacology, can result in more innovative solutions and a better understanding of complex biological systems. High Attrition Rates The attrition rate in drug discovery is notably elevated. Numerous compounds do not succeed in clinical trials owing to issues related to efficacy or safety. This high failure rate contributes to the cost and time required to develop new drugs. Predictive Models: The utilization of artificial intelligence and machine learning in the development of predictive models can facilitate the early identification of potential failures in the process, enabling researchers to concentrate their efforts on the most promising candidates. Biomarkers and Diagnostics: Incorporating biomarkers and diagnostic tools in clinical trials can improve patient selection and increase the likelihood of success by targeting specific populations more likely to respond to the treatment. ...Read more
Strict regulatory adherence is essential to uphold the integrity of the pharmaceutical industry. As one of the most tightly regulated sectors globally, this oversight is justified by the critical role that medication safety, efficacy, and outcomes play in protecting human health. Significance of Compliance in Pharma Industry Pharmaceutical compliance is crucial for several reasons within the pharmaceutical sector. Among the most critical factors contributing to the necessity of maintaining compliance in this industry are: Safeguarding Public Health:  Adherence to regulations guarantees the safety of medications and treatments, minimizing the risk of adverse effects. Proper labeling and advertising of pharmaceuticals are essential to this compliance, providing patients with the necessary information regarding the products they use. Preserving Industry Reputation and Integrity:  Compliance plays a crucial role in sustaining the industry's reputation. It fosters trust among consumers and enhances confidence among healthcare professionals and stakeholders. Conversely, failure to comply can result in scandals, tarnish a company's reputation, and erode public trust. Adhering to Ethical and Legal Standards:  Upholding ethical standards is paramount in the healthcare and pharmaceutical sectors due to the significant implications involved. A moral obligation exists to ensure that the medications prescribed and administered do not cause harm, thereby contributing positively to public health. Eliminate Fines and Penalties: Pharmaceutical companies are required to adhere to the regulations and guidelines established by various authorities, such as the FSSAI, to legally market their products. Failure to comply with these regulations may result in significant penalties, fines, and potential bans, which can adversely affect the company's financial standing and reputation. Ensure Product Quality:  Following good manufacturing practices is crucial to guaranteeing that medicines are produced consistently in accordance with established quality standards. Financial Implications: Achieving full compliance fosters confidence among insurers and investors, leading to enhanced capital investment opportunities and mitigating the risk of legal disputes or issues for the company. Pharmaceutical compliance encompasses multiple business facets, including research and development, clinical trials, manufacturing, marketing, sales, and distribution. Regulatory Compliance in the Pharma Industry Regulatory compliance pertains to the obligation to follow the laws, regulations, and guidelines established within the pharmaceutical industry that oversee pharmaceutical product development, manufacturing, marketing, and distribution. These regulations, instituted by governmental authorities, ensure that the products manufactured and distributed are safe, effective, and of the utmost quality. ...Read more
The pharmaceutical industry, long reliant on large-scale technology platforms, is now at a critical juncture in its digital transformation. These platforms, often marketed as comprehensive solutions, promised to streamline operations, accelerate research, and speed up market entry. Yet, with growing platform saturation, a major shift is underway. Companies are increasingly moving away from the vendor dependency that defined the past decade and embracing a new era of technology-agnostic advisory services. This approach emphasizes a deep understanding of each organization’s unique needs rather than the imposition of pre-configured solutions, marking a significant transition from a “solution-centric” to a “problem-centric” mindset. From Solution-First to Platform Fatigue The conventional paradigm of technology consulting within the pharmaceutical sector was predicated mainly on a "solution-first" methodology. In this model, the vendor or consultant would introduce a proprietary platform or a pre-assembled suite of tools and promptly articulate the company's operational requirements in the context of that specific technology. The discourse typically commenced with an assertion such as, "This is our platform, and this is how it can address all your challenges." While seemingly expedient, this approach frequently resulted in several unforeseen ramifications. The appeal of a singular, integrated platform was considerable, promising simplicity, a unified data environment, and a direct route to modernization. Nevertheless, the actual implementation frequently proved far more intricate. The "all-in-one" platform seldom aligned seamlessly with a company's distinct processes, leading to extensive, costly, and protracted customization initiatives. These customizations, in turn, fostered a reliance on the platform's vendor, thereby rendering future transitions to alternative solutions exceptionally challenging and expensive. This phenomenon constitutes the core of vendor lock-in. This led to the gradual formation of a heterogeneous collection of inflexible systems. A rigid and unwieldy technological infrastructure supplanted the initial expectation of streamlined operations. With the rapid evolution of technology, these legacy systems have evolved into a considerable impediment. They impeded innovation, complicated integration with novel, specialized tools, and ultimately decelerated the very processes they were designed to expedite. This persistent challenge with unwieldy systems, combined with the recognition that their technological trajectory was dependent on a single vendor, fostered a pervasive sense of platform disillusionment. Leaders began to scrutinize the efficacy of a system that offered comprehensive solutions but delivered restricted flexibility and autonomy. The Inevitable Move Away from Vendor Lock-in The fundamental flaw in a solution-centric approach is its tendency to impose the solution upon the problem, rather than allowing the situation to dictate the solution. This represents a suboptimal alignment for an industry as intricate and extensively regulated as the pharmaceutical sector. The distinct requirements of drug discovery, clinical trials, and manufacturing are profoundly subtle and can exhibit substantial variation even within a singular enterprise. This shift away from vendor lock-in directly addresses the inherent inflexibility of singular, monolithic platforms. Organizations now recognize that such comprehensive solutions are rarely optimal for every segment of their value chain. Consequently, they are pursuing a more modular and adaptable strategy, enabling them to select specialized, best-of-breed technologies tailored to specific functions, ranging from advanced AI tools for molecular design to dedicated platforms for clinical trial data management or robust systems for supply chain logistics. The imperative for future-proofing also fuels this pursuit of flexibility. The rapid pace of technological innovation, particularly within domains such as artificial intelligence and data science, dictates that the optimal solution of today may quickly become obsolete. An enterprise constrained by a singular vendor's ecosystem is precluded from readily adopting these nascent advancements without incurring substantial and costly overhauls. By emancipating themselves from this limitation, organizations can maintain agility and competitiveness, seamlessly integrating new tools as they emerge, thereby obviating the need for a complete technological overhaul. The Problem-First Paradigm In response to these industry shifts, tech-agnostic advisory services are gaining prominence. This model fundamentally inverts the traditional approach, commencing not with a solution, but with a thorough, unbiased investigation of the problem. A tech-agnostic advisor does not arrive with a preconceived notion of which technology to implement. Instead, they function as a neutral party, primarily assisting the company in defining its core business challenges. Once the problem is clearly defined and its root causes are understood, the advisor can then explore the entire universe of available technologies to find the optimal solution. This might involve a combination of different platforms, a bespoke software development project, or the strategic integration of existing systems. Crucially, the recommendation is based on what is genuinely the best fit for the problem, not what the advisor has to sell. This approach empowers pharmaceutical companies to build a truly modern and resilient technology stack. Instead of a rigid, all-or-nothing system, they can create a flexible, interoperable ecosystem. This enables them to select specialized tools that excel in their specific domain, resulting in more effective and efficient operations. The long-term benefit is a more adaptable organization that can evolve with the changing technological landscape and maintain a strategic advantage. The rise of tech-agnostic advisory is not just a change in how technology is bought; it’s a shift in how pharmaceutical companies think about technology itself—as a set of tools to solve problems, rather than a solution to be purchased. The age of platform fatigue has fostered an environment where pharmaceutical leaders necessitate heightened levels of transparency, adaptability, and authentic collaboration in the realm of digital strategy. The emergence of technology-agnostic, problem-centric advisory services effectively addresses this demand. This shift signifies a maturation within the industry, characterized by a departure from proprietary constraints and biases, and a concurrent investment in comprehensive knowledge, deliberate integration, and solutions predicated on demonstrable business outcomes rather than ephemeral trends. As the industry continues its evolutionary trajectory, the imperative to adapt swiftly while maintaining focus on core objectives will remain paramount. In this context, technology-agnostic advisory represents not merely a transient inclination but a long-term, strategic necessity for pharmaceutical enterprises navigating digital complexities with characteristic perspicuity and resolve. ...Read more

Weekly Brief